JPS5925373A - Sulfonate derivative - Google Patents

Sulfonate derivative

Info

Publication number
JPS5925373A
JPS5925373A JP13395782A JP13395782A JPS5925373A JP S5925373 A JPS5925373 A JP S5925373A JP 13395782 A JP13395782 A JP 13395782A JP 13395782 A JP13395782 A JP 13395782A JP S5925373 A JPS5925373 A JP S5925373A
Authority
JP
Japan
Prior art keywords
compound
formula
methylene chloride
halogen
reduced pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP13395782A
Other languages
Japanese (ja)
Inventor
Senji Kakeya
掛谷 宣治
Susumu Nishizawa
西沢 進
Satoshi Tamaki
田巻 聰
Hiroshi Matsui
博 松井
Masayasu Kasai
正恭 笠井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto Pharmaceutical Industries Ltd
Original Assignee
Kyoto Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Pharmaceutical Industries Ltd filed Critical Kyoto Pharmaceutical Industries Ltd
Priority to JP13395782A priority Critical patent/JPS5925373A/en
Publication of JPS5925373A publication Critical patent/JPS5925373A/en
Pending legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

NEW MATERIAL:A compound of formula I (X and X' are halogen; R is alkyl). EXAMPLE:alpha-Chloroethyl-chlorosulfonate. USE:Useful as a synthetic intermediate for compounds, e.g. penicillin and cephalosporin, etc. PROCESS:A compound of the formula X-SO3H is slowly dropped into a compound of formula III (Y is halogen), and the resultant reaction mixture is separated and purified by the well-known method, e.g. distillation, etc. to give the compound of formula I in high yield.

Description

【発明の詳細な説明】 本発明は新規スルホネ−ト誘導体に関する。[Detailed description of the invention] The present invention relates to novel sulfonate derivatives.

本発明者らは、一般式 %式% (1) (式中、X及びX′はそれぞれ)10ゲン原子を、■は
アルキルJj(を示す。)で表わされるスルホネ−1・
誘導体を創製することに成功すると共電こ当該化合物+
1) 、!、;、たとえばペニシリン、セファロス」ソ
1ノンその細化合物の合成中間体として有用であること
を見出して本発明を完成しtこ。
The present inventors have developed a sulfone-1.
If we succeed in creating a derivative, Kyodo will develop the compound +
1) ,! We have completed the present invention by discovering that, for example, penicillin and cephalosolone are useful as intermediates for the synthesis of their fine compounds.

即ち1本発明は化合物tl)を提供するものである。That is, the present invention provides compound tl).

一般式(1)に関してX及びX′におけるハロゲン原子
としては、塩素原子、ヨウ素原子、臭素原子などが列挙
でれる。
Regarding the general formula (1), examples of the halogen atom in X and X' include a chlorine atom, an iodine atom, a bromine atom, and the like.

また、一般式fl)に関してRで示されるアルキル基は
、il!−f鎖状1分枝状のいずれでもよく、その好ま
しい炭素原子数は1〜4である。かかるアルキル基の具
体例としては、jことえばメチノペエチル、n−プロピ
ル、1so−プロピル、n−ブチル、1so−ブチルな
どがあげられる。
In addition, the alkyl group represented by R in the general formula fl) is il! -f It may be either linear or mono-branched, and the preferred number of carbon atoms is 1 to 4. Specific examples of such alkyl groups include methinopeethyl, n-propyl, 1so-propyl, n-butyl, 1so-butyl, and the like.

本発明化合物(11は、たとえば次の様にして製造され
る。
The compound of the present invention (11) is produced, for example, as follows.

(方法1) 一般式 %式%([1 (Xは前記と同意@) で表わされる化合物と一般式 怠義)で表わされる化合物を反応させる方法。(Method 1) general formula % expression % ([1 (X agrees with the above @) Compound and general formula represented by A method of reacting compounds represented by

一般式(III)においてYで示されるハロゲン原子と
してはx、 x’におけるハロゲン原子と同様の本シり
が例示さ1れる。
Examples of the halogen atom represented by Y in the general formula (III) include the same halogen atoms as x and x'.

化合物in)と化合物1111)との反応は、化合物t
m)を化合物+I++中に滴下することによって行って
もよいが、化合物1ll)を化合物(1「)中に滴下す
る方が収率が良いので好ましい。
The reaction between compound in) and compound 1111) results in compound t
Although it may be carried out by dropping m) into compound +I++, it is preferable to drop compound 111) into compound (1'') because the yield is better.

(方法2) 化合物trnと一般式 %式%) (式中、Rは前記と同意義)で表わされる化合物とを反
応させる方法。
(Method 2) A method of reacting the compound trn with a compound represented by the general formula % (% formula %) (wherein R has the same meaning as above).

かくして得られる1的化合物[1)は、自体既知の手段
、たとえば蒸留などによって分離、精製されろ。
The single compound [1] thus obtained is separated and purified by means known per se, such as distillation.

本発明に係る化合物+1+は、種々化合物の合成中間体
として有用である。たとえば、化合物fl+を式() (式中、Aはt−ブチル基葡示す9又はその金属塊(N
a塩、K塩等)と反応させることによって(式中、X−
几、Aは前記と同意義。)が得られるが、この化合物(
M)は、たとえばセファロスポリン誘導体、ペニシリン
誘導体などのエステル化剤として有用でアル。
Compound +1+ according to the present invention is useful as a synthetic intermediate for various compounds. For example, the compound fl+ is expressed by the formula () (where A is t-butyl group 9 or its metal mass (N
a salt, K salt, etc.) (in the formula, X-
几 and A have the same meaning as above. ) is obtained, but this compound (
M) is useful as an esterifying agent for, for example, cephalosporin derivatives and penicillin derivatives.

ところで、化合物+11を原料とするエステル化剤であ
る化合物■)の合成に当っては、室温、中性などの緩和
f(条件下で反応が進行するので、〜:?性又は熱など
に不安定な置換基を有する場合でも容易に当該エステル
が得られる。また、当該化合物へnに−てエステル化さ
れたセファロスポリン誘導体、ペニシリン誘導体などは
適度な脂溶性の付与が容易となるので、経口投与にてよ
り吸収されうるものの合成が可能となる、しかも、かく
して得られたセファロスポリン誘導体、ペニシリン誘導
体は、これを経口投与した場合、通常の経口投与用セフ
ァロスポリン、ペニシリンなどにしばしばみられるホル
ムアルデヒドの発生がないところから、極めて毒性の低
いものである。
By the way, in the synthesis of Compound (1), which is an esterifying agent using Compound +11 as a raw material, the reaction proceeds under relaxed f (conditions such as room temperature, neutrality, etc.). The ester can be easily obtained even when it has a stable substituent.Also, cephalosporin derivatives, penicillin derivatives, etc. that are esterified with n to the compound can easily impart appropriate fat solubility. It is possible to synthesize substances that can be absorbed by oral administration, and when the cephalosporin derivatives and penicillin derivatives obtained in this way are administered orally, they often differ from ordinary oral cephalosporins, penicillins, etc. It has extremely low toxicity as it does not generate formaldehyde.

本発明化合物+1)カニら経口投与可能なセファロスポ
リン誘導体の製造工程の一例を示せば次の通りである。
An example of the manufacturing process of the compound of the present invention +1) orally administrable cephalosporin derivative is as follows.

化合物(11 化合物■) OO 実施例1 て徐々に滴下する。その後、ガスの発生が止む迄、同温
度にて1)γ拌する。
Compound (11 Compound ■) OO Example 1 is gradually added dropwise. Thereafter, 1) γ stirring was performed at the same temperature until gas generation stopped.

その後、反応溶液に冷塩化メチレン、氷水を加えしばら
く攪拌し、二相を分離する。水層をさらに冷塩化メチレ
ンにて抽出し、先の塩化メチレン層と合せて冷冷炭酸水
素ナトリウム溶液、次いで冷飽和食塩水にて充分に洗浄
し、芒硝にて乾燥する。その後、減圧下、塩化メチレン
を留去し、残渣を減圧蒸留すると311(収率56Φ)
のα−クロルエチル−クロルスルホネートが得うれる。
Thereafter, cold methylene chloride and ice water are added to the reaction solution and stirred for a while to separate the two phases. The aqueous layer is further extracted with cold methylene chloride, combined with the previous methylene chloride layer, thoroughly washed with cold sodium bicarbonate solution, then cold saturated brine, and dried over Glauber's salt. Thereafter, methylene chloride was distilled off under reduced pressure, and the residue was distilled under reduced pressure to give 311 (yield 56Φ)
.alpha.-chloroethyl-chlorosulfonate is obtained.

l!ll1点:54〜56°C(2Qm+x)I g 
)1420−.11り90.900,790,6901
.99 (ct、 aH,J=6Iiz、  CH3)
6.48 (q、 LH,J=6Hz、 −CH)実施
例2 実施例1と同様にしてα−クロルプロピルクロルホルメ
ートが得られる。、沸点65〜70°C(15mJ(g
) ド4.49pを徐々に加え、30分同温度にて攪拌する
。その後に2S04約1.5yを加え、しばらく攪拌し
、塩化メチレン及び氷水を加える。二相を分離口、水J
ulをさらに塩化メチレンにて抽出し、先の塩化メチレ
ン層と合せて冷冷炭酸水嵩ナトリウム溶液、冷飽和食塩
水にて充分洗浄し、芒硝にて乾燥する。その後、塩化メ
チレンを減圧下留去し、残渣を減圧蒸留すると、α−ク
ロルエチルクロルスル小ネート1.Oyが得られる(収
率12%)。
l! ll1 point: 54-56°C (2Qm+x)I g
)1420-. 11ri90.900,790,6901
.. 99 (ct, aH, J=6Iiz, CH3)
6.48 (q, LH, J=6Hz, -CH) Example 2 α-chloropropyl chloroformate is obtained in the same manner as in Example 1. , boiling point 65-70°C (15 mJ (g
) Gradually add 4.49p of methane and stir at the same temperature for 30 minutes. After that, add about 1.5y of 2S04, stir for a while, and add methylene chloride and ice water. Separate two phases, water J
The ul is further extracted with methylene chloride, and the mixture is combined with the methylene chloride layer, thoroughly washed with cold sodium carbonate solution and cold saturated saline, and dried over sodium sulfate. Thereafter, methylene chloride was distilled off under reduced pressure, and the residue was distilled under reduced pressure to obtain α-chloroethyl chlorsulfate 1. Oy is obtained (yield 12%).

参考例1 1′−クロルエチル−4−(N−t−ブトキシカルボニ
ル−グリシル)アミノ−安息否酸の合成・・1、水の2
00d中に← (N−1−ブトキシカルボニル−グリシ
ル)アミノ−安Ja杏M 0.2 モル、炭if水索す
トリウム0.76モルを加え、しばらく攪拌する。その
後、塩化メチジ2200M/、重硫酸テトラ−n−ブチ
ルアンモニウム0.02モル、α−クロルエチルクロル
スルホネー ト(実施例1の化合物)023モルを順次
加え、室温にて2〜3時間、激しく攪拌する。後、二相
を分1ニーqiCL、水層を塩化メチレンにて抽出し、
先の塩化メチレノ層と合せて、減圧留去する。残渣に酢
酸エチルを加え、飽和食塩水にて充分洗浄し、硫酸マグ
ネシウムにて乾燥する。後、酢酸エチルを減圧留去する
と、標的化合物が収率61%で得られろ。
Reference Example 1 Synthesis of 1'-chloroethyl-4-(N-t-butoxycarbonyl-glycyl)amino-benzoic acid...1, water 2
Add 0.2 mole of (N-1-butoxycarbonyl-glycyl)amino-anjam and 0.76 mole of thorium to the solution and stir for a while. Thereafter, 2200 M of methidichloride, 0.02 mol of tetra-n-butylammonium bisulfate, and 0.23 mol of α-chloroethyl chlorosulfonate (compound of Example 1) were sequentially added, and the mixture was vigorously heated at room temperature for 2 to 3 hours. Stir. After that, the two phases were extracted with qiCL for 1 min, and the aqueous layer was extracted with methylene chloride.
The mixture is combined with the methylene chloride layer and evaporated under reduced pressure. Add ethyl acetate to the residue, wash thoroughly with saturated brine, and dry over magnesium sulfate. Thereafter, ethyl acetate was distilled off under reduced pressure to obtain the target compound in a yield of 61%.

IR(Nujol、 tan ’) : 1735.1
675.160ONMR(CD3C#、 ppm): 1、48 (s 、 9H1OJ(3X8 )1.92
 (d、 J=6Hz、 3H1CJjH3)3.96
(d−J−6Hz、2H1OH2)5、50 (t 、
 J =6 I(z 、L HlNT(OH2)6.7
7 (q、 J=6I−Iz、 IH,−OH−)7、
60 、8.02 (d、 d、 J=9Hz、 4■
1.  c6n、 )−8、76(b r 、 L H
,−NI■−)参考例2 1′−(4−グリシルアミノ−安息香酸)−エチル−7
−C2−(2−アミノチアゾール−4−イセフエムー4
−カルボキシレート塩酸塩の合成参考例1の化合物6m
モルをアセトン中ヨウ化ナトリウム302nモルと公知
の方法にて反応させることにより得られる粗ヨードメチ
ルエステル体を単離精製することなく、7−(2−(2
−アミナトリウ(ム4mモルの40m?ジメチルホルム
アミド溶液に一20°Cで加えそのままIO分〜1時間
攪拌する。その後、酢酸エチルを加え、希炭酸水素ナト
リウム溶液次いで飽和食塩水にてよく洗浄し、芒硝にて
乾燥する。その後、酢酸エチルを減圧下留去し、イソプ
ロピルエーテルにて結晶化することにより得られたL’
−(4−(N−t−ブトキシカルボニル−グリシル)ア
ミノ−安A[jm〕−エチル−7−[2−(2−アミノ
チアゾール−4−イル−2−メトキシイミノアセトアミ
ド〕−#エム−4−カルホキシレーh O,5ynモル
を、下記の脱保護基反応法に従って処理することによシ
、標記化合物を収率54%で得る。
IR (Nujol, tan'): 1735.1
675.160ONMR (CD3C#, ppm): 1,48 (s, 9H1OJ (3X8) 1.92
(d, J=6Hz, 3H1CJjH3) 3.96
(d-J-6Hz, 2H1OH2)5,50 (t,
J = 6 I(z, L HlNT(OH2)6.7
7 (q, J=6I-Iz, IH, -OH-)7,
60, 8.02 (d, d, J=9Hz, 4■
1. c6n, )-8, 76 (br, L H
, -NI■-) Reference Example 2 1'-(4-Glycylamino-benzoic acid)-ethyl-7
-C2-(2-aminothiazole-4-isefuemu 4
- Synthesis of carboxylate hydrochloride Compound 6m of Reference Example 1
7-(2-(2
- Aminatrium (4 mmol) is added to a 40 m² dimethylformamide solution at -20°C and stirred for 10 minutes to 1 hour. Then, ethyl acetate is added, and the mixture is thoroughly washed with a dilute sodium hydrogen carbonate solution and then with saturated brine. Dry with Glauber's salt. Then, ethyl acetate is distilled off under reduced pressure, and L' obtained by crystallizing with isopropyl ether.
-(4-(N-t-butoxycarbonyl-glycyl)amino-anA[jm]-ethyl-7-[2-(2-aminothiazol-4-yl-2-methoxyiminoacetamide)]-#m-4 The title compound is obtained in a yield of 54% by treating 5yn moles of -carboxyleneh O, according to the deprotecting group reaction method described below.

IR(Nujol、crn−”): L775,173
5.1700、)630,160O NMR(CD3(JD、 pi)m) :1.69 (
d、 J=6Hz、 3H,−CH5)2.14 (a
、 3H,C5−CH5)3.36〜3.72 (m、
 2H,C2−H2)3.98 (at 2HI  N
H2)4.12 (s、 3H,−0CH3)5.18
 (d、 J=5Hz、 1’H,C6−H)5.86
 (d、 J=5Hz、  LH,C7−H)7.10
 (s、  LH,チアゾール5−H)7.27   
((1,J=6:)lz、   LH,−CH−)7.
75 and 8.05 (d、 d、 J=9Hz、
 4H,−C6H4)(脱保訛基反応法) 当該化合物0.5mモルを3〜6mlの酢酸に溶解し、
飽和塩化水素酢酸溶液2〜4mlを加え、室温にて10
〜30分攪拌する。その後、酢酸エチルを加え、析出結
晶全ろ取し、酢酸エチルにて洗浄することによシ標記化
合物を得る。
IR (Nujol, crn-”): L775,173
5.1700,) 630,160O NMR (CD3(JD, pi)m): 1.69 (
d, J=6Hz, 3H,-CH5)2.14 (a
, 3H, C5-CH5) 3.36-3.72 (m,
2H, C2-H2) 3.98 (at 2HI N
H2) 4.12 (s, 3H, -0CH3) 5.18
(d, J=5Hz, 1'H, C6-H)5.86
(d, J=5Hz, LH, C7-H)7.10
(s, LH, thiazole 5-H) 7.27
((1, J=6:)lz, LH, -CH-)7.
75 and 8.05 (d, d, J=9Hz,
4H, -C6H4) (Deprotection group reaction method) Dissolve 0.5 mmol of the compound in 3 to 6 ml of acetic acid,
Add 2 to 4 ml of saturated hydrogen chloride acetic acid solution and stir at room temperature for 10
Stir for ~30 minutes. Thereafter, ethyl acetate was added, all precipitated crystals were collected by filtration, and the title compound was obtained by washing with ethyl acetate.

Claims (1)

【特許請求の範囲】[Claims] (1)一般式 %式% (式中、X及びではそれぞれ)10ゲン原子を、几はア
ルキル基を示す。)で表わされるスルホネート誘導体。
(1) General formula % Formula % (In the formula, X and each represent 10 gene atoms, and 几 represents an alkyl group. ) A sulfonate derivative represented by
JP13395782A 1982-07-31 1982-07-31 Sulfonate derivative Pending JPS5925373A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP13395782A JPS5925373A (en) 1982-07-31 1982-07-31 Sulfonate derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13395782A JPS5925373A (en) 1982-07-31 1982-07-31 Sulfonate derivative

Publications (1)

Publication Number Publication Date
JPS5925373A true JPS5925373A (en) 1984-02-09

Family

ID=15117027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13395782A Pending JPS5925373A (en) 1982-07-31 1982-07-31 Sulfonate derivative

Country Status (1)

Country Link
JP (1) JPS5925373A (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SYNTHESIS=1973 *

Similar Documents

Publication Publication Date Title
EA002452B1 (en) Processes and intermediates useful to make antifolates
JPH04134077A (en) Isoxazole compound
JPS5892672A (en) Manufacture of cephalosporins, intermediate and manufacture
KR20190044652A (en) Method for producing indolecarboxamide compound
JP7241682B2 (en) Method for preparing deuterated imidazolidinedione compounds
JPS61218580A (en) 2-(2-amino-4-thiazolyl)-2-methoxyiminoacetic acid derivativeand manufacture
JPS5925373A (en) Sulfonate derivative
JPS596308B2 (en) Tetrazole thiol derivative
JP2769058B2 (en) Preparation of cyclopropane derivatives
JP4886948B2 (en) Biphenylethylamine derivative and method for producing the same
JP3074665B2 (en) Method for producing novel hydrazone compounds and triazole compounds
JPS61165351A (en) Production of oxyphenylmalonic half ester
JP3214139B2 (en) Method for producing pantothenic acid derivative
JP3669726B2 (en) Process for producing optically active 3- (p-alkoxyphenyl) glycidic acid ester derivative
WO2003080643A1 (en) Process for producing triterpene derivative
JPH03204852A (en) Production of norbornane-based sulfonamide derivatives
JPH02295946A (en) Substituterd biphenylcarboxylic acid and preparation thereof
JPH0150219B2 (en)
JPS58164573A (en) Manufacture of 1-(4-chlorobenzoyl)-5-methoxy- 2-methyl-3-indole acetoxyacetic acids
JPH0219349A (en) 2-(4,5-dihalo-2-nitrobenzoyl)-3-cyclopropylaminoacrylic ester and production thereof
JPS60100571A (en) Dioxole derivative
JP2001302611A (en) Method for producing 5-trifluoromethyldihydrouracil
JPH0119384B2 (en)
JPH0586016A (en) Azulene derivative, thromboxane a2 and prostaglandin endoperoxide acceptor antagonist and production thereof
JPS6038353A (en) Production of epsilon-guanidino-eta-caproic acid rho-ethoxycarbonylphenyl ester